ENZB update: Beryl Capital files 13G/A showing zero stake

Rhea-AI Filing Summary

Enzo Biochem (ENZB): Schedule 13G/A filed by Beryl Capital entities shows no current stake. Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP, and David A. Witkin reported 0 shares and 0% beneficial ownership of Enzo Biochem common stock (CUSIP 294100102) as of 09/30/2025.

The filing affirms the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. Item 5 indicates ownership of five percent or less of the class. All voting and dispositive powers are listed as 0.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

ENZO BIOCHEM INC

(Name of Issuer)

Common Stock

(Title of Class of Securities)

294100102

(CUSIP Number)

09/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 294100102

1

Names of Reporting Persons

Beryl Capital Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. 294100102

1

Names of Reporting Persons

Beryl Capital Management LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

CUSIP No. 294100102

1

Names of Reporting Persons

Beryl Capital Partners II LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 294100102

1

Names of Reporting Persons

David A. Witkin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ENZO BIOCHEM INC
(b)	Address of issuer's principal executive offices: 21 Executive Blvd., Farmingdale, NY 11735
Item 2.
(a)	Name of person filing: Beryl Capital Management LLC, a Delaware limited liability company ("Beryl") Beryl Capital Management LP, a Delaware limited partnership ("Beryl GP") Beryl Capital Partners II LP, a Delaware limited partnership (the "Partnership") David A. Witkin Beryl is the investment adviser to the Partnership and other accounts. Beryl is the general partner of Beryl GP, which is the general partner of the Partnership and other private investment funds. Mr. Witkin is the control person of Beryl. Each reporting person disclaims beneficial ownership of Common Stock except to the extent of that person's pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any Common Stock covered by this Schedule 13G.
(b)	Address or principal business office or, if none, residence: 225 Avenue I, Suite 205 Redondo Beach, CA 90277
(c)	Citizenship: See Item 4 of the cover sheet for each reporting person.
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 294100102
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Beryl: 0 Beryl GP: 0 Partnership: 0 David A Witkin: 0
(b)	Percent of class: Beryl: 0% Beryl GP: 0% Partnership: 0% David A. Witkin: 0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Beryl: 0 Beryl GP: 0 Partnership: 0 David A. Witkin: 0
	(ii) Shared power to vote or to direct the vote: Beryl: 0 Beryl GP: 0 Partnership: 0 David A Witkin: 0
	(iii) Sole power to dispose or to direct the disposition of: Beryl: 0 Beryl GP: 0 Partnership: 0 David A. Witkin: 0
	(iv) Shared power to dispose or to direct the disposition of: Beryl: 0 Beryl GP: 0 Partnership: 0 David A Witkin: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Beryl Capital Management LLC

Signature:	/s/ Andrew Nelson
Name/Title:	Chief Operating Officer
Date:	11/14/2025

Beryl Capital Management LP

Signature:	/s/ Andrew Nelson
Name/Title:	Chief Operating Officer of Beryl Capital Management LLC, General Partner of Beryl Capital Management LP
Date:	11/14/2025

Beryl Capital Partners II LP

Signature:	/s/ Andrew Nelson
Name/Title:	COO of Beryl Capital Management LLC, General Partner of Beryl Capital Management LP, General Partner of Beryl Capital Partners II LP
Date:	11/14/2025

David A. Witkin

Signature:	/s/ David A. Witkin
Name/Title:	Reporting person
Date:	11/14/2025

Exhibit Information

Exhibit 99 - Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G

FAQ

What did Enzo Biochem (ENZB) disclose in this Schedule 13G/A?

A group led by Beryl Capital filed an amended Schedule 13G reporting 0 shares and 0% beneficial ownership of Enzo Biochem common stock.

Who are the reporting persons in the ENZB Schedule 13G/A?

The reporting persons are Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP, and David A. Witkin.

What percentage of Enzo Biochem’s common stock do the filers report?

They report 0% of the class, with 0 shares beneficially owned.

What is the event date referenced in the ENZB filing?

The event date is 09/30/2025.

Does the filing state any intent to influence control of Enzo Biochem?

No. The certification states the securities were not acquired or held to change or influence control.

What are the voting and dispositive powers reported?

Each reporting person lists 0 for sole and shared voting power and 0 for sole and shared dispositive power.

What class and CUSIP are covered in this ENZB filing?

It covers Common Stock, CUSIP 294100102.